These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17481749)

  • 1. A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis.
    Oliver LN; Buttner PG; Hobson H; Golledge J
    Int J Cardiol; 2008 May; 126(2):216-23. PubMed ID: 17481749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular brachytherapy versus drug-eluting stents in the treatment of in-stent restenosis: A meta-analysis of long-term outcomes.
    Benjo A; Cardoso RN; Collins T; Garcia D; Macedo FY; El-Hayek G; Nadkarni G; Aziz E; Jenkins JS
    Catheter Cardiovasc Interv; 2016 Feb; 87(2):200-8. PubMed ID: 25963829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
    Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
    JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in-depth review of retrospective studies to assess the role of vascular brachytherapy for the treatment of complex patients with multiple risk factors for DES-ISR.
    Mittal A; Dhaliwal SS; Bhullar D; Dass J
    Rev Cardiovasc Med; 2022 Feb; 23(2):54. PubMed ID: 35229545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular brachytherapy for patients with drug-eluting stent restenosis.
    Bonello L; Kaneshige K; De Labriolle A; Roy P; Lemesle G; Torguson R; Satler LF; Pichard AD; Lindsay J; Waksman R
    J Interv Cardiol; 2008 Dec; 21(6):528-34. PubMed ID: 18973502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
    Babapulle MN; Joseph L; Bélisle P; Brophy JM; Eisenberg MJ
    Lancet; 2004 Aug 14-20; 364(9434):583-91. PubMed ID: 15313358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Vascular Brachytherapy and Stenting for the Treatment of In-Stent Restenosis.
    Chen Y; Buchanan KD; Chan RC; Zhang C; Torguson R; Satler LF; Waksman R
    Am J Cardiol; 2020 Mar; 125(5):712-719. PubMed ID: 31889523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis.
    Saia F; Lemos PA; Hoye A; Sianos G; Arampatzis CA; de Feyter PJ; van der Giessen WJ; Smits PC; van Domburg RT; Serruys PW
    Catheter Cardiovasc Interv; 2004 Jul; 62(3):283-8. PubMed ID: 15224289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stents versus repeat vascular brachytherapy for patients with recurrent in-stent restenosis after failed intracoronary radiation.
    Chu WW; Torguson R; Pichard AD; Satler LF; Chan R; Porrazzo M; Kent KM; Suddath WO; Waksman R
    J Invasive Cardiol; 2005 Dec; 17(12):659-62. PubMed ID: 16327049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy.
    Yerasi C; Chen Y; Case BC; Forrestal BJ; Shea C; Zhang C; Torguson R; Ben-Dor I; Satler LF; Waksman R
    Am J Cardiol; 2021 Mar; 142():44-51. PubMed ID: 33285089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial.
    Ellis SG; O'Shaughnessy CD; Martin SL; Kent K; McGarry T; Turco MA; Kereiakes DJ; Popma JJ; Friedman M; Koglin J; Stone GW;
    Eur Heart J; 2008 Jul; 29(13):1625-34. PubMed ID: 18556716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.
    Holmes DR; Teirstein P; Satler L; Sketch M; O'Malley J; Popma JJ; Kuntz RE; Fitzgerald PJ; Wang H; Caramanica E; Cohen SA;
    JAMA; 2006 Mar; 295(11):1264-73. PubMed ID: 16531619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and angiographic one-year follow-up of vascular beta-brachytherapy for coronary lesions treated by a stent with a very high risk for restenosis].
    Schiele TM; Pöllinger B; Kantlehner R; Dühmke E; Theisen K; Klauss V
    Dtsch Med Wochenschr; 2003 May; 128(20):1103-8. PubMed ID: 12748899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up.
    Cortese B; Bertoletti A; De Matteis S; Danzi GB; Kastrati A
    Int J Cardiol; 2012 Nov; 161(2):73-82. PubMed ID: 21570728
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.